A review of the cost of cardiovascular disease

Canadian Journal of Cardiology

Volumn 25, Issue 6, 2009, Pages

  Tarride, Jean Eric ^a,b   Lim, Morgan ^a,b   DesMeules, Marie ^c   Luo, Wei ^c   Burke, Natasha ^a,b   O'Reilly, Daria ^a,b   Bowen, James ^a,b   Goeree, Ron ^a,b  

^a MCMASTER UNIVERSITY   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

^c Centre for Chronic Disease Prevention and Control   (Canada)

Author keywords

Cardiovascular disease; Cost illness; Health economics; Health policy; Outcomes research; Review

Indexed keywords

AUSTRALIA; CANADA; CARDIOVASCULAR DISEASE; CONGESTIVE HEART FAILURE; CORONARY ARTERY DISEASE; COST OF ILLNESS; DRUG COST; ECONOMIC EVALUATION; EUROPE; HEALTH CARE COST; HOSPITAL CHARGE; HOSPITALIZATION COST; HUMAN; HYPERTENSION; MEDICAL FEE; REVIEW; STROKE; UNITED STATES; ECONOMICS; HEART FAILURE;

AUSTRALIA; CANADA; CARDIOVASCULAR DISEASES; EUROPE; HEART FAILURE; HUMANS; HYPERTENSION; STROKE; UNITED STATES;

EID: 67649946485     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0828-282X(09)70098-4     Document Type: Article

References (42)

1. World Health Organization. Cardiovascular disease: Prevention and control. Global strategy on diet, physical activity and health. 2007. (Version current at August 8, 2007).
2. Centers for Disease Control and Prevention. Division for heart disease and stroke prevention: Addressing the nation's leading killers. At a glance 2007. Chronic Disease Prevention. (Version current at August 8, 2007).
3. Statistics Canada. Mortality: Summary list of causes 2003. Catalogue number 84F0209XIE. Ottawa: Minister of Industry, 2006. (Version current at March 4, 2006).
4. OANDA Corporation. (Version current at August 8, 2007).
5. Organization for Economic Co-operation and Development. Consumer price indices (MEI). OECD.Stat. The organization. (Version current at August 8, 2007).
6. OECD. Country statistical profiles 2007. OECD.Stat. (Version current at August 8, 2007).
7. World Health Organization. Point prevalence for selected causes: By sex, age and WHO subregion. (Version current at August 8, 2007).
8. American Heart Association. Heart disease and stroke statistics - 2006 update: A report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2006;113:e85-e151.
9. Birnbaum H, Leong S, Kabra A. Lifetime medical costs for women: Cardiovascular disease, diabetes, and stress urinary incontinence. Womens Health Issues 2003;13:204-13.
10. Garis RI, Farmer KC. Examining costs of chronic conditions in a Medicaid population. Managed Care 2002;11:43-50.
11. Health Canada. Economic Burden of Illness in Canada in 1998. Ottawa: Health Canada, 2002. (Version current at August 8, 2007).
12. Leal J, Luengo-Fernandez R, Gray A, Petetsen S, Rayner M. Economic burden of cardiovascular diseases in the enlarged European Union. Eur Heart J 2006;27:1610-9.
13. Sasser AC, Rousculp MD, Birnbaum HG, Oster EF, Lufkin E, Mallet D. Economic burden of osteoporosis, breast cancer, and cardiovascular disease among postmenopausal women in an employed population. Womens Health Issues 2005;15:97-108.
14. Wang G, Pratt M, Macera CA, Zheng ZJ, Heath G. Physical activity, cardiovascular disease, and medical expenditures in U.S. adults. Ann Behav Med 2004;28:88-94.
15. Chan B, Hayes B. Cost of stroke in Ontario, 1994/95. CMAJ 1998;159(6 Suppl):2-8.
16. Dewey HM, Thrift AG, Mihalopoulos C, et al. Cost of stroke in Australia from a societal perspective: Results from the North East Melbourne Stroke Incidence Study (NEMESIS). Stroke 001;32:2409-16.
17. Ekman M. Economic evidence in stroke: A review. Eur J Health Econ 2004;5(Suppl 1):S74-S83.
18. Goeree R, Blackhouse G, Petrovic R, Salama S. Cost of stroke in Canada: A 1-year prospective study. J Med Econ 2005;8:147-67.
19. Kolominsky-Rabas PL, Heuschmann PU, Marschall D, et al. Lifetime cost of ischemic stroke in Germany: Results and national projections from a population-based stroke registry: The Erlangen Stroke Project. Stroke 2006;37:1179-83.
20. Samsa GPB. Epidemiology of recurrent cerebral infarction: A medicare claims-based comparison of first and recurrent strokes on 2-year survival and cost. Stroke 1999;30:338-49.
21. Sloan FA, Taylor DH Jr, Picone G. Costs and outcomes of hip fracture and stroke, 1984 to 1994. Am J Public Health 1999;89:935-7.
22. Teng J, Mayo NE, Latimer E, et al. Costs and caregiver consequences of early supported discharge for stroke patients. Stroke 2003;34:528-36.
23. Truelsen T, Ekman M, Boysen G. Cost of stroke in Europe. Eur J Neurol 2005;12(Suppl 1):78-84.
24. Rossnagel K, Nolte CH, Muller-Nordhorn J, et al. Medical resource use and costs of health care after acute stroke in Germany. Eur J Neurol 2005;12:862-8.
25. Amin S, Mullins C, Duncan B, Blanford L. Direct health care costs for treatment of diabetes mellitus and hypertension in an IPA-group-model HMO. Am J Health Syst Pharm 1999;56:1515-20.
26. Berto P, Degli EE, Ruffo P, et al. The pandora project: Cost of hypertension from a general practitioner database. Blood Press 2002;11:151-6.
27. Degli Esposti E, Berto P, Ruffo P, Buda S, Degli Esposti L, Sturani A; Pandora Study Group. The PANDORA project: Results of the cost of illness analysis. J Hum Hypertens 2001;15:329-34.
28. Druss BG, Marcus SC, Olfson M, Tanielian T, Elinson L, Pincus HA. Comparing the national economic burden of five chronic conditions. Health Affairs 2001;20:233-41.
29. Garis RI, Farmer KC. The incremental cost of chronic illnesses: A medicaid database analysis. J Res Pharm. Econ 2001;11:21-41.
30. Goetzel RZ, Long SR, Ozminkowski RJ, Hawkins K, Wang S, Lynch W. Health, absence, disability, and presenteeism cost estimates of certain physical and mental health conditions affecting U.S. employers. J Occup Environ Med 2004;46:398-412.
31. Hodgson TA, Cai L. Medical care expenditures for hypertension, its complications, and its comorbidities. Medical Care 2001;39:599-615.
32. Kiiskinen U, Vartiainen E, Puska P, Aromaa A. Long-term cost and life-expectancy consequences of hypertension. J Hypertens 1998;16:1103-12.
33. Maetzel A, Li LC, Pencharz J, Tomlinson G, Bombardier C, Community Hypertension and Arthritis Project Study Team. The economic burden associated with osteoarthritis, rheumatoid arthritis, and hypertension: A comparative study. Ann Rheum Dis 2004;63:395-401.
34. Xuan J, Duong PT, Russo PA, Lacey MJ, Wong B. The economic burden of congestive heart failure in a managed care population. Am J Manag Care 2000;6:693-700.
35. Eisenstein EL, Shaw LK, Anstrom KJ, et al. Assessing the clinical and economic burden of coronary artery disease: 1986-1998. Medical Care 2001;39:824-35.
36. Etemad LR, McCollam PL. Total first-year costs of acute coronary syndrome in a managed care setting. J Manag Care Pharm 2005;11:300-6.
37. Javitz HS, Ward MM, Watson JB, Jaana M. Cost of illness of chronic angina. Am J Manag Care 2004;10(11 Suppl):S358-S369.
38. Levy E, Gabriel S, Diner J. The comparative medical costs of atherothrombotic disease in European countries. Pharmacoeconomics 2003;21:651-9.
39. Liu JL, Maniadakis N, Gray A, Rayner M. The economic burden of coronary heart disease in the UK. Heart 2002;88:597-603.
40. Migliaccio-Walle K, Caro JJ, Ishak KJ, O'Brien JA. Costs and medical care consequences associated with the diagnosis of peripheral arterial disease. Pharmacoeconomics 2005;23:733-42.
41. Russell MW, Huse DM, Drowns S, Hamel EC, Hartz SC. Direct medical costs of coronary artery disease in the United States. Am J Cardiol 1998;81:1110-5.
42. Stewart S, Murphy N, Walker A, McGuire A, McMurray JJ. The current cost of angina pectoris to the National Health Service in the UK. Heart 2003;89:848-53.